| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Acamprosate calcium (also known as Campral EC), a medication used in the treatment of alcohol dependence, is a GABA receptor agonist and modulator of glutamatergic systems; it reduces alcohol consumption in animal models of alcohol addiction. Acamprosate is thought to stabilize the chemical balance in the brain that would otherwise be disrupted by alcohol withdrawal. Reports indicate that acamprosate works to best advantage in combination with psychosocial support and can help facilitate reduced consumption as well as full abstinence. Until it became a generic in the United States, Campral was manufactured and marketed in the United States by Forest Laboratories, while Merck KGaA markets it outside the US.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation No information is available on the clinical use of acamprosate during breastfeeding. Based on its chemical properties it is likely to enter milk. However, the oral bioavailability of acamprosate is only 11%, so systemic effects in the breastfed infant are unlikely. If acamprosate is required by the mother, it is not a reason to discontinue breastfeeding. Monitor the breastfed infant for diarrhea. ◉ Effects in Breastfed Infants Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk Relevant published information was not found as of the revision date. |
||
| References |
|
||
| Additional Infomation |
Acamprosate calcium is an organic calcium salt. It contains an acamprosate(1-).
Structural analog of taurine that is used for the prevention of relapse in individuals with ALCOHOLISM. See also: Acamprosate (has active moiety). |
| Molecular Formula |
C10H20CAN2O8S2
|
|
|---|---|---|
| Molecular Weight |
400.47
|
|
| Exact Mass |
400.028
|
|
| CAS # |
77337-73-6
|
|
| Related CAS # |
Acamprosate-d3 calcium;1225580-94-8;Acamprosate;77337-76-9
|
|
| PubChem CID |
155434
|
|
| Appearance |
White to off-white solid powder
|
|
| Melting Point |
>300ºC
|
|
| LogP |
1.059
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
8
|
|
| Rotatable Bond Count |
6
|
|
| Heavy Atom Count |
23
|
|
| Complexity |
202
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
BUVGWDNTAWHSKI-UHFFFAOYSA-L
|
|
| InChi Code |
InChI=1S/2C5H11NO4S.Ca/c2*1-5(7)6-3-2-4-11(8,9)10;/h2*2-4H2,1H3,(H,6,7)(H,8,9,10);/q;;+2/p-2
|
|
| Chemical Name |
Calcium 3-(acetylamino)propane-1-sulfonate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4971 mL | 12.4853 mL | 24.9707 mL | |
| 5 mM | 0.4994 mL | 2.4971 mL | 4.9941 mL | |
| 10 mM | 0.2497 mL | 1.2485 mL | 2.4971 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06269627 | NOT YET RECRUITING | Drug: Acamprosate calcium Other: Placebo |
Alcohol Use Disorder | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 2024-07-04 | Phase 4 |
| NCT03634917 | COMPLETED | Drug: Acamprosate Calcium Drug: Calcium Carbonate Drug: Placebo Drug: Placebo lead in |
Alcoholism | Technische Universität Dresden | 2020-08-05 | Phase 3 |
| NCT02217007 | WITHDRAWN | Drug: SNC-102 sustained release tablet | Tourette Syndrome | Synchroneuron Inc. | 2015-04 | Phase 2 |
| NCT00591565 | COMPLETEDWITH RESULTS | Drug: Acamprosate | Anxiety | State University of New York - Upstate Medical University | 2006-06 | Not Applicable |
| NCT02064010 | WITHDRAWN | Drug: SNC-102 Drug: Placebo |
Drug-induced Tardive Dyskinesia | Synchroneuron Inc. | 2014-02 | Phase 2 |
Ethanol exposure in a vapor chamber and ethanol withdrawal experiment.Neuropharmacology. 2012 Jun;62(8):2480-8. |
|---|
 |
Simplified illustration of the cortical-striatal circuit in ENT1 null mice.Neuropharmacology. 2012 Jun;62(8):2480-8. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
